Table 3. Prediction of MMR achievement at 12 months with the use of different EMR markers.

		Analysis with (BCR-ABL1/ABL1)IS					Analysis with BCR-ABL1/GUS
EMR marker		Cut-off	No. of patients	OR	95% CI	p	Cut-off	No. of patients	RR	95% CI	p
Transcript level at 3 months (%)
TKI1
Low risk		≤0.99	28	23.81	5.45–104.1	<0.001	≤0.36	27	20.00	4.67–85.60	<0.001
High risk		>0.99	27				>0.36	28
TKI2
Low risk		≤0.99	16	16.50	2.51–108.6	0.003	≤0.36	14	6.88	1.35–35.07	0.027
High risk		>0.99	13				>0.36	15
All TKI
Low risk		≤0.99	44	18.21	6.08–54.54	<0.001	≤0.36	41	12.55	4.38–35.92	<0.001
High risk		>0.99	40				>0.36	43
Halving time (days)
TKI1
Low risk		≤19	31	33.25	7.39–149.6	<0.001	≤21	30	36.00	7.69–168.6	<0.001
High risk		>19	24				>21	25
TKI2
Low risk		≤19	15	10.08	1.82–56.02	0.009	≤21	14	6.88	1.35–35.07	0.027
High risk		>19	14				>21	15
All TKI
Low risk		≤19	46	20.89	6.81–64.08	<0.001	≤21	44	18.21	6.08–54.54	<0.001
High risk		>19	38				>21	40
Log reduction
TKI1
Low risk		≤1.70	31	25.65	6.08–108.3	<0.001	≤1,45	32	19.44	4.91–76.96	<0.001
High risk		>1.70	24				>1,45	23
TKI2
Low risk		≤1.70	16	16.50	2.51–108.6	0.003	≤1,45	16	16.50	2.51–108.6	0.003
High risk		>1.70	13				>1,45	13
All TKI
Low risk		≤1.70	47	20.89	6.81–64.08	<0.001	≤1,45	48	17.95	5.98–53.86	<0.001
High risk		>1.70	37				>1,45	36

We compared the ability 3 early molecular response (EMR) markers recently described (transcript level at 3 months, Halving time and transcript log reduction) to accurately predict the achievement of major molecular response (MMR) after 12 months of treatment, either with the use of ABL1 or GUS as control gene. Optimal cut-off for each marker was identified by using receiver operating characteristic (ROC) curve. Relative risks are expressed as odds ratios (OR) with 95% confidence interval (95% CI).